Korttids hepatitt C-behandling av heroinavhengige pasienter

Tidsskrift for den Norske Laegeforening

Volumn 129, Issue 16, 2009, Pages 1639-1642

  Kristensen, Øistein ^a   Sundøy, Anders ^b   Skeie, Karin ^a   Vederhus, John Kåre ^a   Øye, Ingebjørg ^b   Opsal, Anne ^b   Rysstad, Ole ^c   Gallefoss, Frode ^d  

^a Avdeling for Rus og Avhengighetsbehandling   (Norway)

^b Infeksjonsmedisinsk seksjon   (Norway)

^c Medisinsk avdeling   (Norway)

^d Lungeseksjonen   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CLASSIFICATION; FEMALE; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEROIN DEPENDENCE; HUMAN; MALE; PATIENT CARE; PROSPECTIVE STUDY; SUBSTANCE ABUSE; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEROIN DEPENDENCE; HUMANS; INTERFERON ALFA-2B; MALE; PATIENT CARE TEAM; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70249113387     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.09.33690     Document Type: Article

References (17)

1. Bell H, Dalgard O, Bjøro K et al. Behandling ved kronisk hepatitt C. Tidsskr Nor Lægeforen 2002; 122: 926-8.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2005; 345: 41-52.
3. Deuffic-Burban S, Wong JB, Valleron AJ et al. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40: 319-26.
4. Dalgard O, Jeansson S, Skaug K et al. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol 2003; 38: 864-70.
5. Kristensen O, Espegren O, Asland R et al. Buprenorfin og metadon til opiatavhengige - en randomisert studie. Tidsskr Nor Lægeforen 2005; 125: 148-51.
6. Dalgard O, Egeland A, Ervik R et al. Risikofaktorer for hepatitt C-smitte blant sprøytenarkomane. Tidsskr Nor Legeforen 2009; 129:101-4.
7. NIH Consensus Development Program. Management of Hepatitis C. http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm, (30.3.2009).
8. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40:1260-5.
9. Ide T, Kumashiro R, Hino T et al. Short term and two-step interferon therapy for chronic hepatitis C patients with low HCV RNA levels. Hepatol Res 2002; 22: 145-51.
10. Nomura H, Tsuchiya Y, Maruyama T et al. The effects of a high dose, short course of interferon on hepatitis C. J Gastroenterol Hepatol 1999; 14: 85-9.
11. Lagging M, Langeland N, Pedersen et al. Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47: 1837-45.
12. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavivirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
13. Vik ISS, Skaug K, Dalgard O et al. Hepatitt C - et helseproblem også i Norge. Tidsskr Nor Legeforen 2008; 128: 563-6.
14. Svanborg P, Asberg M. A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale(MADRS). J Affect Disord 2001; 64: 203-16.
15. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale, preliminary report. Psychol Bull 1973; 9: 13-28.
16. Mauss S, Berger F, Goelz J et al. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40: 120-4.
17. Krook AL, Stokka D, Heger B et al. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res 2007; 13: 216-21.